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Background: The complex pathophysiology of migraine is not yet clearly understood; therefore, 
experimental models are essential for the investigation of the processes related to migraine 
headache, which include cortical spreading depression (CSD) and NO donor-induced neurovas-
cular changes. Data on the assessment of drug efficacy in these models are often limited, which 
prompted us to investigate a novel combined migraine model in which an effective pharmacon 
could be more easily identified.
Materials and methods: In vivo electrophysiological experiments were performed to 
investigate the effect of nitroglycerin (NTG) on CSD induced by KCl application. In addition, 
sumatriptan and newly synthesized neuroactive substances (analogues of the neuromodulator 
kynurenic acid [KYNA]) were also tested.
Results: The basic parameters of CSDs were unchanged following NTG administration; how-
ever, propagation failure was decreased compared to the controls. Sumatriptan decreased the 
number of CSDs, whereas propagation failure was as minimal as in the NTG group. On the other 
hand, both of the KYNA analogues restored the ratio of propagation to the control level.
Discussion: The ratio of propagation appeared to be the indicator of the effect of NTG. This is 
the first study providing direct evidence that NTG influences CSD; furthermore, we observed 
different effects of sumatriptan and KYNA analogues. Sumatriptan changed the generation of 
CSDs, whereas the analogues acted on the propagation of the waves. Our experimental design 
overlaps with a large spectrum of processes present in migraine pathophysiology, and it can be 
a useful experimental model for drug screening.
Keywords: migraine, cortical spreading depression, nitroglycerin, sumatriptan, kynurenic 
acid analogues
Introduction
Migraine is one of the most common neurological disorders, affecting 17% of women 
and 6% of men in the US.1 The environmental triggers eliciting migraine headache 
are diverse. The characteristic phases include aura (in a third of patients), headache, 
nausea, and hypersensitivity. In subgroups of patients, migraine headache is a well-
managed condition; however, the therapeutic efficacy of available antimigraine drugs 
is in many cases limited, which necessitates unabated research efforts. The two main 
categories in migraine therapy include the acute and the preventive (ie, prophylactic) 
approaches. In acute therapy, different triptans (eg, sumatriptan) and nonsteroidal 
anti-inflammatory drugs are mainly used, whereas calcium-channel blockers, serotonin 
(ie, 5-hydroxytriptamine [5-HT]) antagonists, and β-blockers are among the drugs 
used for prophylaxis. Even though the research related to the processes involved in the 
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pathomechanism of migraine has been a focus for decades, 
these have not yet been fully elucidated. Therefore, animal 
experiments are essential for further investigation of the 
pathophysiological processes related to migraine headache, 
and also for testing new substances aimed at mitigation of 
symptoms. The different mechanisms of migraine can be 
investigated from various aspects by a number of experimen-
tal models based on the sensitization or the stimulation of 
the trigeminal system, including the investigation of cortical 
spreading depression (CSD) and changes in the neurovascular 
system induced by NO donors.2
CSD is the electrophysiological correlate of migraine aura, 
and represents a potential trigger for headache.3 It is an intense 
self-propagating wave of depolarization involving neuronal 
and glial cells in the cerebral cortex, which is independent 
of functional areas and arterial territories.4 CSD spreads at a 
velocity of 3–6 mm/min and causes massive changes in ionic 
homeostasis. Glutamatergic mechanisms have primary roles 
in the propagation of CSD. Indeed, CSD cannot be induced 
in cases of either P/Q-type calcium channels or N-methyl-d-
aspartate (NMDA) receptors being blocked in brain slices in 
vitro,5 or when antagonists of calcium channels or NMDA 
receptors are used in vivo.6,7 In addition, CSD upregulates 
several receptors in hippocampal and striatal territories, such 
as γ-aminobutyric acid A, different cholinergic (M
1/2
, α
1/2
), 
5-HT serotonergic, and D
1
 dopaminergic, as well as NMDA-, 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid- 
and kainate-sensitive glutamatergic receptors.8,9 Therefore, 
in addition to glutamatergic mechanisms, alterations in other 
neurotransmitter systems participate in CSD as well. CSD 
also has an effect on cerebral blood flow, being associated 
with an initial increase in the blood flow via arteriolar dilation 
(mediated predominantly by NO), which subsequently turns 
into long-term oligemia.10,11
Experimental administration of NO donors, such as 
nitroglycerin (NTG), is a widely used method to model 
head pain. NTG elicits headache in both animals and 
humans.12,13 Systemic NTG administration evokes alterations 
in meningeal and cortical blood flow,14,15 increases the level of 
calcitonin gene-related peptide, and induces c-Fos expression 
in different brain areas associated with pain perception.16
With the use of these migraine models, several promising 
substances acting via various mechanisms can be investigated. 
The neuroactive metabolites of the kynurenine system pro-
vide a spectrum of possibilities to interfere with different 
neuropathological processes.17,18 Following the publication 
of the first studies suggesting the role of kynurenines in 
migraine,19 a subsequent series of research proved the 
beneficial effects of kynurenine-related pharmacologi-
cal manipulations in migraine models.20,21 Among these 
substances, kynurenic acid (KYNA) has potential neuro-
protective action by interfering with glutamatergic excito-
toxicity. The peripheral administration of KYNA provides 
a number of promising results; however, these effects are 
limited, because of the low penetration of KYNA through 
the blood–brain barrier.22 Therefore, structurally modified 
KYNA derivates with better pharmacokinetic profiles may 
serve as useful tools against a large spectrum of neuropatho-
logical processes.
In this study, our aim was to investigate the effect of NTG 
on CSD, so as to create and validate a combined experimental 
migraine model, enabling the investigation of antimigraine 
drugs and the selection of other substances affecting the 
pathomechanism of migraine for further examinations. Also, 
we applied NTG with other molecules, including sumatriptan 
and novel analogues of KYNA, prior to the induction of 
CSD to test our combined experimental migraine model and 
investigate the effects of these molecules in this setting.
Materials and methods
animals and surgery
All procedures used in this study were in accordance with 
the guidelines of the European Communities Council Direc-
tives (2010/63/EU) and the Hungarian Act for the Protection 
of Animals in Research (XXVIII.tv. 32. §). The study was 
approved by the National Scientific Ethical Committee on 
Animal Experimentation (National Competent Authority 
in Hungary), with the license number XX./842/2016. Male 
Wistar rats weighing 250–300 g were used. Animals were 
housed in polyethylene cages at room temperature (22°C) 
with a 12-hour light–dark cycle (lights on at 6 am) and free 
access to water and rodent laboratory chow.
All procedures were carried out under deep urethane 
anesthesia (1.5±0.2 g/kg body weight), as it provides very 
stable anesthesia in rats, lasting for several hours and being 
optimal for CSD recordings.23,24 During surgery and CSD 
recordings, the animals breathed spontaneously, and their 
body temperature was maintained at 37°C±0.5°C by the 
use of a self-regulating heating pad (TMP 5-b; Supertech 
Instruments, Budapest, Hungary) and a rectal probe. A tra-
chea cannula was inserted, and heads of the animals were 
fixed in a stereotaxic frame. After exposure of the skull, 
three holes (2 mm in diameter) were drilled on the left side 
under cooling with saline with 3 mm between each hole (see 
Figure 1). Two holes were used for electrophysiological 
recordings above the sensorimotor cortex (bregma [Br] 1, 2 
for E
1
, -2, 2 for E
2
, indicating distances in millimeters in 
the anterior–posterior and the medial–lateral axes from the 
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effect of nTg administration on cortical spreading depression
Br, respectively). In the third hole (Br -5, 2), the dura and 
arachnoid mater were carefully removed, allowing access for 
the chemical induction of CSD. Before the recordings, the 
cortex was allowed to recover for 30 minutes.
electrophysiological recordings
Both the slow direct current (DC)-potential change and spon-
taneous cortical electrical activity accompanying CSD were 
continuously recorded for 4 hours. For the DC recordings, 
glass microelectrodes (1.5–2 MΩ) filled with artificial cere-
brospinal fluid connected to an Ag/AgCl wire were inserted 
into the cortex to a depth of 800±100 μm, corresponding to 
cortical layer V. Electrocorticography (ECoG) was recorded 
from the surface of the dura with the aid of a silver electrode 
next to the posterior DC electrode (Br -2, 2). ECoG was 
recorded to monitor the depth of anesthesia and to verify the 
CSDs that cause a notable reduction in the ECoG amplitudes 
(Figure 1). In both types of recordings, common reference 
electrodes of the same type were placed in the masticatory 
muscle. DC-potential changes and ECoG were recorded by 
connecting the electrodes to EXP-E amplifiers (Experimetria 
Ltd, Budapest, Hungary).
Following offline data processing with laboratory-
developed software, we examined the frequency, amplitude, 
time to half amplitude, velocity of propagation, and propaga-
tion failure of the CSD waves. Furthermore, we compared 
these parameters separately between the two recording DC 
electrodes (E
1
, E
2
) and between the first and second hour of 
recording following KCl application. The velocity of CSD-
wave propagation was calculated from the time required 
for a CSD wave to travel the distance between the two 
cortical recording points. This time was measured by using 
the beginning of the first descending phase of the slow DC-
potential change as the initial point, as previously described 
by Batista-de-Oliveira et al.25 DC shifts not exceeding the 
threshold of 5 mV were excluded from data analysis.
experimental groups and treatments
The applied pharmacons and the saline (used as control and 
vehicle) were injected intraperitoneally prior to KCl admin-
istration at the given time point (Figure 2). The control group 
(n=6) received 2.5 mL of saline, whereas the NTG group 
(n=5) was treated with 10 mg/kg NTG (Nitro Pohl; G Pohl-
Boskamp GmbH and Co KG, Hohenlockstedt, Germany) 
at minute 10. In the NTG + sumatriptan group (n=5), 
sumatriptan (Imigran; GlaxoSmithKline PLC, London, 
UK) at a dose of 0.6 mg/kg was applied 10 minutes after 
the NTG injection, in accordance with Bates et al.26 The 
KYNA analogues (SZR-105 and SZR-109; each n=5) were 
both administered at a dose of 0.5 mmol/kg at minute 90 
(80 minutes after NTG administration, 30 minutes before 
CSD induction).
The KYNA analogues SZR-105 and SZR-109 are novel 
neuroactive KYNA derivatives, substituted at C3. According 
Figure 1 experimental design and representative recording from the 2-hour period following Kcl administration.
Notes: On the left, filled circles indicate the exposed skull areas (1, -2, and -5 mm from the bregma in the anterior–posterior axis, respectively; 2 mm from the bregma in 
the medial–lateral axis). KCl (1 M) was applied at the posterior hole. Direct-current electrodes E1 and e2 were positioned at a distance of 3 mm from each other. The silver 
electrocorticography electrode was placed next to the e1 electrode. Vertical bars 10 mV (direct current) and 500 μV. horizontal bar 10 minutes.
(
(
.&,
Figure 2 experimental design of the different groups. numbers represent hours 
of recording.
Abbreviations: nTg, nitroglycerin; csD, cortical spreading depression; suma, 
sumatriptan.
   
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to preliminary studies, these molecules might be effective 
neuroprotective or effective compounds in certain neurologi-
cal diseases (eg, in Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease, amyotrophic lateral sclerosis, stroke, 
multiple sclerosis, and migraine).
In all groups, CSD waves were continuously elicited for 
2 hours from the 120th min by placing a cotton ball (diameter 
1 mm) soaked with 1 M KCl solution onto the cortex through 
the posterior hole. To keep the cotton ball moist, it was 
impregnated with 5 μL of KCl solution every 15 minutes.
statistical analysis
IBM SPSS 20 software was used for the analyses. Electro-
physiological data between the two electrodes were com-
pared separately by the use of nonparametric related-sample 
Friedman two-way analysis of variance (ANOVA) by rank. 
To analyze the differences between the groups, nonpara-
metric independent-sample Kruskal–Wallis ANOVA was 
used. Data are expressed as mean and standard devia-
tion. Differences were considered statistically significant 
when P#0.05.
Results
The slow potential change in the DC-potential recordings 
clearly denoted the presence of CSDs after KCl stimulation, 
which could also be easily detected by the farther, second 
DC electrode (E
2
). In some cases, more CSDs were detected 
by E
2
, which can be attributed to a very slight depolarization 
of the area under E
1
.
After analysis of the data, the amplitude, velocity, and time 
to half amplitude of the CSDs showed no significant differ-
ences between the groups (Table 1). None of these parameters 
differed significantly when comparing the data obtained from 
the two electrodes separately (Table 1) or when comparing 
the first and the second hour (data not shown). However, 
a slight increase in the amplitudes was observed at E
2
.
In the control group, we observed a constantly occurring 
propagation failure (20%±1%) (Figure 3A), which resulted 
in decreased CSD numbers recorded by E
2
. This tendency 
was observed in almost all the recordings (Figure 3A), 
and proved to be significant (P=0.046) based on pairwise 
comparison (two-way Friedman’s ANOVA). The CSD 
numbers (similarly to all other groups) recorded by either 
E
1
 or E
2
 showed no difference between the first and second 
hours of KCl administration (E
1
 9.3±4, 10.5±4; E
2
 8.0±3, 
7.4±2) (Figure 3B).
The administration of NTG slightly but insignificantly 
elevated CSD numbers and significantly changed the ratio of 
propagation (1.02±0.1). In this case, no significant difference 
was observed between the electrodes, as opposed to the con-
trol group (Figure 3A). In the NTG + sumatriptan group, CSD 
numbers decreased when sumatriptan was applied 10 minutes 
after NTG treatment. Significant differences were detectable 
in multiple comparisons of CSD numbers recorded by E
2
 in 
the different groups (Figure 3B). In this group, the ratio of 
propagation (1.03±0.1) was similar to that in the NTG group 
(Figure 3A and C).
Both of the KYNA analogues applied after NTG injection 
restored CSD numbers and the ratio of propagation to the 
control level (Figure 3). In each animal (n=5 in both KYNA 
analogue-treated groups), the number of CSDs at E
2
 was 
less than or at most equal with that observed at E
1
, which 
resulted in significant decreases in related-sample analyses 
(P=0.046 and P=0.025 for the two KYNA-analogue groups, 
respectively; Figure 3A and C).
Discussion
Despite the large amount of accumulated knowledge 
about the processes involved in migraine pathogenesis, the 
available treatments are at present often limited and sub-
optimal. Therefore, new experimental models, candidate 
compounds and drug targets are still the focus of antimigraine 
research.27,28 Cortical excitability in CSD is a physiological 
correlate of aura in migraine,29,30 which prompted us to 
investigate the hypothesis whether NTG can influence the 
characteristics of CSDs.
Table 1 Parameters of csD
n Propagation 
velocity (mm/min)
Amplitude (mV) Time to half 
amplitude (seconds)
Number of CSDs/ 
2 hours
E1 E2 E1 E2 E1 E2
control 6 2.93±0.5 25.41±4.7 29.04±4.6 26.5±12.2 27.39±8 19.83±6.9 15.33±4.1
nTg 5 2.97±0.5 24.96±5 26.24±6.1 24.21±9.1 25.07±8.9 22.6±7.1 22.80±5.7
nTg + suma 5 2.84±0.3 25.87±5.9 28.29±6.9 28.03±6.1 25.54±6.7 13.2±4.1 13.8±5.9*
nTg + sZr-105 5 2.93±0.7 26±5.6 28.53±5.1 28.5±7.2 31.94±8.5 22±3.9 16.8±2.4
nTg + sZr-109 5 2.78±0.4 26.47±5.2 27.95±5.4 29.8±8.6 29.61±7.4 20.6±3.2 15.6±2.1
Notes: *P=0.032 (multiple comparison of NTG groups by Kruskal–Wallis ANOVA); values are mean ± sD.
Abbreviations: csD, cortical spreading depression; nTg, nitroglycerin; suma, sumatriptan; anOVa, analysis of variance; sD, standard deviation.
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effect of nTg administration on cortical spreading depression
Figure 3 csD frequency and ratio of propagation.
Notes: (A) number of csDs/2 hours in all experiments and groups. The connecting lines show the data from single experiments, recorded by e1 and e2. The slope of the lines 
indicates the ratio of propagation, based on the different CSD number recorded by the two electrodes. In this parameter, significant differences were observed in the control 
group and both of the nTg + SZR groups (pairwise comparison within the groups with Friedman’s ANOVA; *P=0.046, 0.046, 0.025). (B) Average (±sD) csD numbers in the 
different groups, detected by e1 and e2. Significant decrease in CSD number recorded by E2 was observed in the nTg + suma group using multiple comparison between the 
groups and electrodes (Kruskal–Wallis ANOVA; +P=0.032). Horizontal lines within bars represents CSD number (mean ± SD) in the first hour. There was no significant difference 
between the first and second hour recorded by either of the electrodes in any groups. (C) Average (±SD) ratio of propagation in the different groups (CSDs at E2/csDs at e1).
Abbreviations: csD, cortical spreading depression; nTg, nitroglycerin; anOVa, analysis of variance; sD, standard deviation; suma, sumatriptan.
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Based on a number of studies, CSD is an “all or none” 
phenomenon, making it difficult to detect remarkable changes 
in various CSD parameters following the acute administration 
of potential antimigraine drugs.31–33 The most relevant CSD 
parameters include the susceptibility (examined by increasing 
electrical stimulation), the frequency (in cases of continuous 
KCl application), and the velocity of SD. Of note, the amplitude 
and the duration are quite constant in most experiments.34
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In the present study, the progression of the depolarization 
wave failed between the two recording points in 20% of the 
CSDs, indicative of the presence of inhibitory effects in 
the cortical tissue under physiological conditions (notably 
during anesthesia). However, the propagation of the CSDs 
was unimpeded after the systemic administration of NTG, 
molecules of which may provide support against homeostatic 
and energetic disturbances caused by the CSDs,35 resulting 
in enhanced propagation. In contrast to our results, some 
studies have proved an inverse relationship between tissue 
NO level and susceptibility in human and rodent cortices36 
and also in chicken retina.37 Low NO level or inhibited NOS 
increased tissue susceptibility to CSD. Furthermore, CSDs 
themselves increase NO levels,38 and thus additional NTG 
may contribute to the release or appearance of other NO 
metabolites. Further investigations are needed to identify the 
detailed mechanisms and to explore the active substances that 
take part in this phenomenon. Nevertheless, in point of fact, 
we suggest that the altered physiological state caused by NTG 
administration can be influenced more easily than the baseline 
parameters of CSDs; therefore, this model may provide an 
opportunity to test compounds with only moderate or subtle 
effects via the assessment of the ratio of propagation. Our 
results clearly demonstrate the effect of NTG administra-
tion on CSD propagation. There have been limited studies 
to investigate the NTG effect on CSD. Read et al confirmed 
that NTG causes elevated brain NO levels in anesthetized 
cats.39 The susceptibility, duration, and amplitude of CSDs 
were not changed by NTG; however, CSD-induced local 
NO concentration was elevated. In another study, Bates 
et al performed experiments on mice to investigate CSD 
susceptibility following NTG administration, but they did 
not find any differences between the groups.26 In our study, 
sumatriptan decreased the frequency of CSDs; however, 
the ratio of propagation remained similar to that seen in the 
NTG group. Sumatriptan has been proven to be effective 
in migraine by acting on the serotonin system through the 
activation of 5-HT
1B/1D
 receptors. Decreased 5-HT level is 
closely associated with headache.40 It is known that 5-HT 
receptors are involved in neurogenic cranial vascular 
changes. Indeed, meningeal blood flow increases following 
the application of the 5-HT
7
-receptor agonist, whereas 
5-HT
7
-receptor antagonist plus sumatriptan as a 5-HT
1B/1D
 
agonist causes decreased blood flow.41 In a prior study, 
sumatriptan decreased the concentration of NO following 
CSD induction,42 and alleviated mechanical and thermal 
allodynia that developed as a result of NTG administration.26 
In a vessel-free preparation of chicken retina, sumatriptan 
blocked the SD in a concentration-dependent manner, which 
indicates that the effect must be related to neuronal tissue.43 
Nevertheless, there is no evidence that sumatriptan can 
strongly modulate CSDs.44,45 In the present study, we cannot 
give a full explanation of the mechanisms underlying our 
results. However, we suggest that the 5-HT receptors directly 
involved in CSD could contribute to this effect.
This is the first study with these novel KYNA analogues 
demonstrating an effect; indeed, the elevated ratio of propa-
gation was restored to the control level by these compounds, 
whereas the number of CSDs remained largely unchanged. 
There are several possibilities to explain these results, includ-
ing the potential modulatory effect of these analogues on 
glutamatergic transmission by means of the inhibition of 
NMDA receptors, similarly to KYNA; however, further 
investigations are needed to be conclusive at this point. The 
beneficial effects of KYNA46 and its different analogues 
have been proven in different migraine models. The KYNA 
analogue SZR-72 mitigated systemic NTG-induced increase 
in the number of neurons expressing c-Fos47 and nNOS.48 
Furthermore, SZR-72 attenuated the NTG-induced decrease 
of histochemical changes in the caudal trigeminal nucleus.49 
The dissimilar effects of sumatriptan and KYNA analogues 
on CSDs suggest two inhibitory mechanisms. Further inves-
tigations are required to clarify the mechanisms underlying 
these effects; however, we can conclude that sumatriptan acts 
on the generation of the waves, whereas KYNA analogues 
interfere with the propagation of CSDs. Nevertheless, we can-
not exclude the possibility that the analogues may counteract 
the effect of NTG and thereby restore normal conditions.
Conclusion
In summary, peripheral administration of NTG enhanced the 
propagation of CSDs. Sumatriptan, a widely used antimigraine 
drug, caused detectable changes in CSD frequency, which indi-
cates the relevance of our model. Additionally, the elevated 
ratio of CSD propagation caused by NTG was decreased by 
SZR-105 and SZR-109. These results clearly show the effec-
tiveness of these promising KYNA analogues. Here, we have 
presented a combined experimental migraine model for testing 
drugs and other pharmacological agents affecting processes 
involved in the pathomechanism of migraine.
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